Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study

Table 2

Baseline population characteristics.

Variable
Female gender	3 (10)
Age (years)	67 ± 8
Waist (cm)	103 ± 9
BMI (kg/m^2)	28 ± 4
Diabetes mellitus
Insulin treated	3 (11)
OHD treated	20 (71)
OHD and Insulin	5 (18)
Mean duration of diabetes mellitus (years)	12 ± 6
Dyslipidemia	25 (86)
Hypertension	25 (86)
Smoking	7 (24)
Clinical presentation
Stable angina	24 (86)
Unstable angina	4 (14)
Previous MI	7 (25)
Previous PCI	15 (53)
Previous CABG	6 (21)
LVEF (%)	56 ± 5
Medications
Aspirin	28 (100)
Clopidogrel	28 (100)
ACEi/ARBs	14 (50)
β-blockers	17 (59)
Statins	21 (74)
Calcium channel blockers	10 (34)
Oral hypoglycemic agents	25 (89)
Biguanides	12 (43)
Sulphonylurea	6 (21)
Biguanides and Sulphonylurea	7 (25)

Values are given as mean ± SD or (%). ACEi/ARBs: angiotensin converting enzyme inhibitors/angiotensin converting enzyme blockers; BMI: body mass index; CABG: coronary artery bypass graft; IGT: impaired glucose tolerance; LVEF: left ventricular ejection fraction; MI: myocardial infarction; OHD: oral hypoglycemic drugs; PCI: percutaneous coronary intervention.